BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The Life Raft Group - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:The Life Raft Group
X-ORIGINAL-URL:https://liferaftgroup.org
X-WR-CALDESC:Events for The Life Raft Group
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260225T120000
DTEND;TZID=America/New_York:20260225T120000
DTSTAMP:20260419T135743
CREATED:20260114T141731Z
LAST-MODIFIED:20260220T204707Z
UID:10001086-1772020800-1772020800@liferaftgroup.org
SUMMARY:Histotripsy Demystified
DESCRIPTION:REGISTERThe Life Raft Group is proud to present “Histotripsy Demystified: Truths and Misconceptions Explained\,” taking place on February 25\, 2026\, from 12:00–1:30 PM ET. \nThis webinar features an expert panel moderated by Dr. Elizabeth Lilley of Brigham and Women’s Hospital with Dr. Hop Tran Cao (MD Anderson Cancer Center)\, Dr. Suzanne George (Dana-Farber Cancer Institute)\, Dr. Christina Angeles (University of Michigan)\, Dr. Alicia Gingrich (University of Nevada/Renown Health System) and Dr. Jiping Wang and Dr. Chandrajit Raut (Brigham and Women’s Hospital/Harvard Medical School). \nThis virtual discussion is open to patient and caregivers of ALL sarcoma types. \nHistotripsy is a noninvasive treatment that uses focused ultrasound to mechanically destroy targeted tissue without surgery\, incisions\, or radiation. The procedure has only recently moved into human clinical trials and clinical use\, with the first FDA clearance for treating liver tumors granted in October 2023 and broader study and adoption continuing through the mid-2020s. \nThis virtual panel discussion will bring together experts from multiple institutions to share diverse perspectives on histotripsy\, including how the technology works\, where the science currently stands\, and common myths and misconceptions. Because histotripsy is being explored across multiple tumor types\, the discussion will be relevant and beneficial to all sarcoma patients seeking to better understand emerging treatment approaches and their potential future role in care. A moderated Q&A segment will follow the discussion. \nThese webinars are for informational purposes only and should not replace professional medical advice. Always consult your healthcare provider before making any treatment or lifestyle changes. \nAbout Our Presenters:\n \nModerator: Dr. Elizabeth Lilley\nBrigham and Women’s Hospital \nDr. Elizabeth Lilley is a surgical oncologist at Brigham and Women’s Hospital specializing in the management of soft tissue sarcomas\, including gastrointestinal stromal tumors (GIST)\, with a special focus on robotic and minimally invasive surgical techniques. Dr. Lilley is triple board certified in surgical oncology\, general surgery\, and palliative medicine. Her research focuses on improving the quality of surgical care for patients with metastatic and recurrent cancers by improving communication surrounding the goals and outcomes of surgery. \nDr. Lilley earned a bachelor’s degree in neuroscience from Lafayette College\, a master’s of public health from Columbia University\, and a medical degree from Rutgers. She completed general surgery residency at Brigham and Women’s Hospital\, followed by the Harvard Interdisciplinary Palliative Care Fellowship. Upon completing fellowship training in Complex General Surgical Oncology at MD Anderson Cancer Center\, she joined the faculty at Brigham and Women’s Hospital and Harvard Medical School\, where she now leads a health services research program centered on the intersection of surgical oncology and palliative care. Her combined expertise in both sarcoma surgery and palliative medicine uniquely positions her to improve the person-centered care of patients with advanced sarcomas. \n \nDr. Christina Angeles\nUniversity of Michigan \nDr. Angeles is an Associate Professor with Tenure of Surgery\, Associate Professor of Dermatology\, and Faculty Member in the Cancer Biology PhD Program at the University of Michigan in the Division of Surgical Oncology. She earned her medical degree at Tufts University School of Medicine. She completed general surgery residency at New York Presbyterian-Weill Cornell Medical Center. While in residency she completed a two-year basic/translational science Surgical Oncology Research Fellowship at Memorial Sloan-Kettering Cancer Center (MSKCC) focusing on the molecular biology and novel therapeutics for sarcoma. After residency\, Dr. Angeles returned to MSKCC and completed a clinical Complex Surgical Oncology Fellowship. Dr. Angeles is board-certified in both General Surgery and Complex General Surgical Oncology. She is the Director of the Regional Cancer Therapies Clinic at University of Michigan/Rogel Cancer Center. \nDr. Angeles is a nationally recognized surgeon-scientist dedicated to advancing cancer care through innovative research and compassionate patient care. As the lead investigator for multiple clinical trials at the Rogel Cancer Center\, she is at the forefront of developing new treatments for melanoma and sarcoma. Her laboratory studies the immune system’s role in fighting cancer\, with a special focus on how resident memory T cells can help create long-lasting protection against tumors. By combining basic science and translational research\, Dr. Angeles and her team are working to transform discoveries in the lab into effective new therapies for patients. Dr. Angeles’s research has been supported by the American Cancer Society\, the Melanoma Research Alliance\, the Society of Surgical Oncology\, and the National Institutes of Health’s National Cancer Institute (NCI-NIH). \n \nDr. Suzanne George\nDana-Farber Cancer Institute \nSuzanne George\, MD is the Division Chief of the Sarcoma Center at Dana-Farber Cancer Institute where leads a team focused on research and clinical care of patients with sarcomas and GIST. She has an extensive research experience in clinical trials and drug development and cares for patient from across New England\, the US and internationally. \n \nDr. Alicia Gingrich\nUniversity of Nevada/ Renown Medical Group \nDr. Gingrich is a surgical oncologist at the University of Nevada\, Reno. She attended medical school at the University of Kansas prior to completing general surgery residency at the University of California\, Davis. She trained at MD Anderson for her complex general surgical oncology fellowship. Dr. Gingrich’s clinical practice focuses on soft tissue sarcoma and GIST as well as hepatobiliary tumors. The University of Nevada\, Reno/Renown were one of the early adopters of Histotripsy and have been performing this procedure for 2 years. She utilizes Histotripsy for select patients with liver tumors. \n \nDr. Chandrajit P. Raut\nChief\, Division of Surgical Oncology\, Mass General Brigham \nDr. Raut is a dedicated surgical oncologist who specializes in the multidisciplinary care of patients with soft tissue sarcoma.  He is a prolific researcher who has received federal funding to investigate sarcoma tumor genetics and identify strategies at reducing sarcoma recurrence rates.  Additionally\, he has served as co-PI or institutional PI on several US and international phase 2 or phase 3 clinical trials evaluating neoadjuvant or adjuvant therapies in various sarcomas. \nDr. Raut is a graduate of Stanford University\, University of Oxford\, and Harvard Medical School.  He completed his general surgery residency at Massachusetts General Hospital and surgical oncology fellowship at M.D. Anderson Cancer Center. \nDr. Raut currently serves as Chair of the AJCC Soft Tissue Sarcoma Staging Panel (9th edition)\, Co-Chair of the Surgery Committee in the cancer cooperative group Alliance for Clinical Trials in Oncology\, and Treasurer on the Executive Board of the Connective Tissue Oncology Society.  In 2013\, he co-founded the Transatlantic Australasian Retroperitoneal Sarcoma Working Group.  He is the former Program Director of the Mass General Brigham/Dana-Farber Complex General Surgical Oncology Fellowship Program at Harvard Medical School.  He serves as Section Editor for sarcoma in the journals Cancer and Surgical Oncology Insights.  He has authored over 300 papers and over 30 book chapters. \n \nDr. Hop Tran Cao\nMD Anderson Cancer Center \nDr. Hop Tran Cao is an Associate Professor and Vice-Chair of Clinical Operations in the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center\, where he specializes in the management of hepatobiliary tumors. He is an expert in minimally invasive surgical techniques and chairs the Minimally Invasive and New Technology in Oncologic Surgery governing committee at MD Anderson. He also chairs the multidisciplinary Histotripsy Steering Committee. \nDr. Tran Cao’s research focuses on improving cancer care quality and precision. He completed his General Surgery residency at the University of California San Diego and his fellowship in Complex General Surgical Oncology at MD Anderson. \n \nDr. Jiping Wang\nBrigham and Women’s Hospital \nDr. Jiping Wang is a surgical oncologist at Brigham and Women’s Hospital. He specializes in treating gastric\, liver\, and pancreatic cancer and soft tissue sarcoma. He has a special interest in using minimally invasive platforms to perform cancer surgeries. In this video he explains robotic surgery for patients.
URL:https://liferaftgroup.org/event/histotripsy-demystified/
CATEGORIES:Education,Events
ORGANIZER;CN="Rebecca Pauley":MAILTO:rpauley@liferaftgroup.org
END:VEVENT
END:VCALENDAR